Literature DB >> 24968688

The prevalence of hemophilia in mainland China: a systematic review and meta-analysis.

Yanji Qu, Xiaolu Nie, Zhirong Yang, Huan Yin, Yuanjie Pang, Peng Dong, Siyan Zhan.   

Abstract

The prevalence of hemophilia in mainland China was unclear; therefore, we can conducted a meta-analysis using existing data to evaluate the prevalence of hemophilia and its subtypes hemophilia A (HA), hemophilia B (HB), hemophilia C (HC) and Von Willebrand disease (VWD) in mainland China. We conducted a systematic literature review during August, 2011 using PubMed, EMBASE, and Cochrane Library in English and CBMDISK, CNKI, VIP and Wanfang Database in Chinese. We also carried out a search of general and specific hemophilia related websites. Reference lists of key reviews were hand-searched for further relevant research. Studies providing data of the prevalence of hemophilia or its subtypes were included. Meta-analysis was done using the generic inverse variance model. Twenty-two studies were included in the meta-analysis. The overall weighted prevalence of hemophilia was 3.6 per 100,000 and the prevalence among males was 5.5 per 100,000. The prevalence based on community studies was 2.9 per 100,000. The proportions of HA, HB, HC and VWD were 70.97%,16.13%,6.45% and 2.90%, respectively. The prevalences calculated in our study were higher than any previous studies in mainland China, but lower than the world-wide prevalences. The registration rate of hemophiliacs was extremely low. HA and HB were the major subtypes of hemophilia.

Entities:  

Mesh:

Year:  2014        PMID: 24968688

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  6 in total

1.  First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China.

Authors:  Renchi Yang; Runhui Wu; Jing Sun; Feifei Sun; Jeremy Rupon; Francois Huard; Joan M Korth-Bradley; Lihong Xu; Binyu Luo; Yingxue Cathy Liu; Pablo Rendo
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

2.  Medical expenditure for patients with hemophilia in urban China: data from medical insurance information system from 2013 to 2015.

Authors:  Guang-Wen Gong; Ying-Chun Chen; Peng-Qian Fang; Rui Min
Journal:  Orphanet J Rare Dis       Date:  2020-06-05       Impact factor: 4.123

3.  Medical costs and hospital utilization for hemophilia A and B urban inpatients in China: a national cross-sectional study.

Authors:  Zhengwei Huang; Stephen Nicholas; Yong Yang; Xiaoping Chen; Elizabeth Maitland; Yong Ma; Xuefeng Shi
Journal:  BMC Health Serv Res       Date:  2022-02-19       Impact factor: 2.655

4.  Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.

Authors:  Rong Chen; Dmitry Gultyaev; Johanna Lister; Rong Han; Nan Hu; Jean Malacan; Alexander Solms; Parth Vashi; Jamie O'Hara; Shanlian Hu
Journal:  BMC Med Res Methodol       Date:  2022-08-05       Impact factor: 4.612

Review 5.  An overview of development in gene therapeutics in China.

Authors:  Dawei Wang; Kang Wang; Yujia Cai
Journal:  Gene Ther       Date:  2020-06-11       Impact factor: 5.250

6.  Health-related quality of life of patients with haemophilia: a cross-sectional survey in the Northeast of China.

Authors:  Jinyu Niu; Liangwen Ning; Qiao Zhang; Ze Liu; Yi Ma; Xiaoxue Xu; Qunhong Wu; Yanhua Hao; Yu Cui; Chaojie Liu
Journal:  BMJ Open       Date:  2022-02-01       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.